Le Lézard
Classified in: Health
Subject: PDT

Takara Bio Announces Launch of Beta Cell Differentiation Service

MOUNTAIN VIEW, Calif., May 17, 2018 /PRNewswire/ -- The Takara Bio Group, the leading provider of human stem cell differentiation services globally, has launched the Cellartis® Directed Differentiation to Beta Cells Service for the delivery of high-quality, custom human induced pluripotent stem cell (hiPSC)-derived beta cells for diabetes research and metabolic disease modeling.

Takara Bio, Inc., Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy.

The gold standard in this field involves the use of primary islets of Langerhans, which are difficult and costly to obtain. Islets containing insulin-secreting beta cells come from donors with different genetic backgrounds, confounding results by adding variability to cellular models and assays. The new differentiation service complements an existing suite of stem cell services and provides a reliable and plentiful source of mature beta cells from customer-specified hiPSCs, enabling beta cell functional studies, diabetes modeling, and compound screening for insulin secretion and regulation.

Catharina Brandsten, Director R&D at Takara Bio Europe AB, said, "Compared with human primary pancreatic islet beta cells, iPS-derived beta cells provide better access to cells and reduced batch-to-batch variability, providing reproducible and biologically relevant data. Our standardized method mimics embryonic development to manufacture large quantities of cryopreserved beta cells that secrete insulin and C-peptide, making the cells an excellent research tool for disease modeling and drug discovery."

About Takara Bio
The Takara Bio Group of companies is committed to improving the human condition through biotechnology. It is led by Takara Bio Inc. which represents the biomedical business interests of its parent company, Takara Holdings Inc. The Takara Bio companies support the life science market through the Takara, Clontech, and Cellartis brands, with the Cellartis brand focusing on stem cell-derived products and services for drug discovery, disease modeling, and applications within regenerative medicine. Learn more about Takara Bio at takara-bio.com (Japanese) and takarabio.com (English).


SOURCE Takara Bio Group

These press releases may also interest you

at 06:45
Eli Lilly and Company today reported that the results of ANNOUNCE, the Phase 3 study of LARTRUVO® (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS), did not confirm the clinical benefit...

at 06:30
Avivagen Inc. ("Avivagen" or the "Company"), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, announces that it has received approval by the TSX Venture Exchange to...

at 06:30
CVS Health and Walmart today announced the companies have reached a multi-year agreement on terms under which Walmart will continue participating in the CVS Caremark pharmacy benefit management (PBM) commercial and Managed Medicaid retail pharmacy...

at 06:15
The "Surgical Site Infection Control - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering. Global Surgical Site Infection Control market accounted for $3705.7 million in 2017 and is expected to reach...

at 06:00
According to the report published by Transparency Market Research, the global wearable medical devices market is expected to reach an estimation of US$ 10 bn by 2023. In 2014, the market earned US$ 2.7 bn. During the forecast period between 2015 and...

at 05:30
Astanza Laser is excited to host Modern Advancements in Aesthetic Lasers on February 21, 2019, a special event coming to the greater Fort Lauderdale / Miami area, located at the Hilton Fort Lauderdale Marina. During this night of innovative...

News published on 17 may 2018 at 08:00 and distributed by: